Acorda Therapeutics: Reiterating Buy Rating With PT=$37 (After Removing Ampyra From The Model)

ACOR

Acorda Therapeutics (ACOR) is down about 24% today after a Delaware district court ruled that 4 patents of Ampyra (marketed for multiple sclerosis) are invalid. One patent was withheld. Ampyra sales are projected to be $53-545 million this year. The company will appeal the court decision.

We consi...

Acorda Therapeutics (ACOR) is down about 24% today after a Delaware district court ruled that 4 patents of Ampyra (marketed for multiple sclerosis) are invalid. One patent was withheld. Ampyra sales are projected to be $53-545 million this year. The company will appeal the court decision.

We consi...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics